

Melbourne, Australia, 7 June 2024

Change of Principal Place of Business

Tryptamine Therapeutics Limited (“**Tryp**” or the “**Company**”) (**ASX: TYP**), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has changed its principal place of business address to the following:

Bio101 Financial Advisory Pty Ltd,
Suite 201,
697 Burke Road,
Camberwell, VIC 3124

The Company’s contact number has also been changed to 03 9092 0475.

All other contact details remain the same.

About Tryptamine Therapeutics Limited

Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%. The Company also recently announced commencement of patient dosing in a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and is preparing to initiate a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety, and patient experience. For more information, please visit www.tryptherapeutics.com.

—ENDS—



This announcement was authorised for issue by the Board of Tryptamine Therapeutics Limited.

For more information, please contact:

Company enquiries

David Franks
Company Secretary
Tryptamine Therapeutics Limited P: +61 2 8098 1169

Corporate enquiries

Cameron Bolton
Alto Capital P: +61 418 944 611

Investor & Media Contact

Peter Molloy
Chief Business Officer
Tryptamine Therapeutics Limited

pmolloy@trypttherapeutics.com

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Tryptamine Therapeutics Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results and developments may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.